General Counsels Accelerate Technology Adoption to Tackle Compliance Pressures
20.5.2025 15:00:00 CEST | Business Wire | Press Release
General counsels (GCs) across the globe are rapidly adopting technology, including generative artificial intelligence (AI), to optimize legal operations and stay on top of growing compliance pressures. This is according to new research conducted among 350 GCs and legal compliance officers across key global markets commissioned by CSC, the world’s leading provider of global business administration and compliance solutions.
CSC’s study1, General Counsel Barometer 2025, reveals that upgrading technology and automation sits firmly at the top of legal departments’ strategic priorities for the year ahead. The majority of legal departments (97%) are already using generative AI, with 49% saying the technology is significantly helping their legal teams.
The most widely reported benefits of AI tools include handling larger volumes of work more efficiently (66%), improving processing times (40%), and enhancing fraud detection and risk management (41%)—highlighting technology’s role in easing pressure on stretched legal teams and strengthening operational resilience.
“Even a year ago, everyone was interested in AI, but at the same time, were still standing on the sidelines and asking how trustworthy it was,” said Thijs van Ingen, global head of Corporate Solutions at CSC. “We’re now seeing real added value and productivity gains, particularly in complex areas like M&A. The shift towards tech-enabled partners shows GCs are acting decisively to modernize their departments in the face of mounting operational pressure.”
Yet confidence is tempered by caution. 72% of GCs have implemented internal governance policies to manage AI use, citing fraud, data privacy, and third-party risks as their top concerns.
“AI is here to stay—but responsible use is key,” added Ian McConnel, chief legal officer at CSC. “GCs are rightly focused on governance, accuracy, and data integrity. As legal teams evolve, they’re becoming leaders in embedding safe, effective AI into core business processes—but success will depend on ensuring the data sets behind these tools are both accurate and robust.”
These shifts are happening against a backdrop of rising compliance demands. Nearly three-quarters (72%) of GCs expect legal and regulatory costs to increase in the next three years, yet only 27% say they feel “very prepared” for new requirements such as expanded beneficial ownership disclosures. The changing regulatory landscape was cited as the number one risk to legal operations in 2025.
As well as embracing technology, nearly six-in-10 (58%) GCs report increased outsourcing to specialist partners—a move driven by resourcing constraints and the need for scalable, tech-enabled support across multiple jurisdictions.
“As organizations pursue global expansion, GCs are leading the charge,” adds van Ingen. “By embedding smarter systems and forming strategic partnerships, GCs are playing a pivotal role in helping their organizations manage risk, drive efficiency, and scale legal operations globally. This marks a defining shift in the role of legal function, where GCs are guiding their organizations into a more agile, tech-enabled future.”
To receive a copy of CSC’s General Counsel Barometer 2025 report, please contact Hassan Ali at cscteam@citigatedewerogerson.com.
1CSC, in partnership with Pure Profile, surveyed 350 general counsels and legal compliance officers in the Americas, Europe including UK, and Asia Pacific in 2025. Survey respondents were drawn from a range of industry sectors including communications, banking and financial services, healthcare, insurance, law, and real estate.
About CSC
CSC is the trusted partner of choice for more than 90% of the Fortune 500®, more than 90% of the 100 Best Global Brands (Interbrand®), and more than 70% of the PEI 300. We are the world’s leading provider of global business administration and compliance solutions, specialized administration services to alternative asset managers across a range of fund strategies, transactions involving capital markets participants in both public and private markets, domain name system management and digital brand and fraud protection, and corporate tax software solutions. Founded in 1899 and headquartered in Wilmington, Delaware, USA, CSC prides itself on being privately held and professionally managed for more than 125 years. CSC has office locations and capabilities in more than 140 jurisdictions across Europe, the Americas, Asia Pacific, and the Middle East. We are a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. We are the business behind business®. Learn more at cscglobal.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250519574808/en/
Contacts
For more information:
Citigate Dewe Rogerson
Hassan Ali | Amber Liu
cscteam@citigatedewerogerson.com
CSC
Laura Crozier
PR Manager
laura.crozier@cscglobal.com
CSC News Room -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cscglobal.
com%2Fservice%2Fpress%2F&esheet=54254846&newsitemid=20250519574808&lan=en-US&anc
hor=CSC+News+Room&index=1&md5=cec24fbd31b89e9857a98470e811e507
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom